Stryker Corporation (SYK) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-11

Business type: Franchise

How it makes money

Stryker earns revenue by selling surgical equipment, instruments, implants, and medical technology directly to healthcare providers worldwide.

Stryker operates through two reportable business segments: MedSurg and Neurotechnology, and Orthopaedics. In 2025, MedSurg and Neurotechnology generated $15,647 million, or 62% of net sales, while Orthopaedics generated $9,469 million, or 38% of net sales.

The company markets its products directly to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches as well as third-party dealers and distributors in approximately 61 countries. Profitability is driven by procedure volumes, successful product launches such as the LIFEPAK 35 and Mako robotic-arm assisted technology, and the company's ability to maintain pricing despite hospital cost containment initiatives.

What protects it: the moat

Management claims competitive protection comes from proprietary technology, regulatory barriers, and direct relationships with healthcare professionals.

Stryker asserts that its market position is supported by unique intellectual property and specialized engineering across multiple product categories, including surgical equipment and joint replacement implants. Regulatory requirements, such as FDA validation rules for materials and components, create hurdles for competitors and alternative suppliers.

However, the filing discloses that many of these advantages rely on sole-source suppliers and complex global supply chains, meaning management's claims of enduring protection are subject to operational disruptions and pricing pressures.

What growth costs

Stryker reinvests capital primarily through research, development and engineering, strategic acquisitions, and ongoing selling, general, and administrative expenses.

To maintain and grow its earnings, Stryker incurs significant operating and capital costs. In 2025, the company spent $1,623 million on research, development and engineering expenses and $8,651 million on selling, general and administrative expenses.

The company also prioritizes capital allocation toward acquisitions, investing $4,960 million in various acquisitions in 2025, alongside paying $1,284 million in dividends to shareholders.

What could damage it

An inability to secure raw materials or sole-source components could halt manufacturing and permanently impair earnings.

Stryker relies on sole-source suppliers for certain raw materials, components, and finished devices due to unique intellectual property and strict regulatory constraints. If these suppliers face financial difficulties, natural disasters, or regulatory embargoes, Stryker may fail to find replacement sources in a timely manner because FDA regulations require rigorous pre-use validation of materials and services.

This inability to manufacture and deliver products would lead directly to lost sales, damaged customer relationships, and a weakened competitive position that could materially impair financial results.

About Stryker Corporation

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

More on SYK

Other companies in Medical Devices